Media releases

Media release: New market research reveals sight is New Zealand's most valued sensePublished 21 May 2025

Nearly nine in 10 New Zealanders would shorten their lives rather than live with vision loss

News release: Exciting news for DLBCL Patients: A New Treatment Option Registered!Published 21 May 2025

Medsafe has registered a new treatment combination: Columvi® (glofitamab) plus chemotherapy (GemOx) in New Zealand

Media release: Ocrevus SC RegistrationPublished 21 May 2025

Media release announcing the registration of Ocrevus SC

Media release : New funding for patients with haemophilia and MSPublished 4 September 2023

Patients with haemophilia and multiple sclerosis set to benefit from Roche’s latest multi-medicine agreement with Pharmac

Media release: First ever agreement between Roche and Iwi Māori tribePublished 11 August 2023

First ever agreement between global pharmaceuticals company and Iwi Māori tribal organisation

Media release : New funding for immunotherapy treatmentPublished 7 March 2023

Roche Products (New Zealand) General Manager Alex Muelhaupt and patient advocate Philip Hope today celebrated new public funding of treatment for lung cancer for patients in New Zealand

Media release: PHARMAC consulting on funding for SMAPublished 19 January 2023

PHARMAC consulting on funding for SMA

Media release: Pharmac proposal for lung cancer treatment fundingPublished 16 December 2022

Multiple new treatments proposed by PHARMAC for lung cancer

Media release : Blood Test for late-stage lung cancerPublished 10 October 2022

Blood test may help improve equity for late-stage lung cancer patients